Class I Phosphatidylinositol 3-Kinases
"Class I Phosphatidylinositol 3-Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphatidylinositol 3-kinase subclass that includes enzymes with a specificity for 1-phosphatidylinositol, 1-phosphatidylinositol 4-phosphate, and 1-phosphatidylinositol 4,5-bisphosphate. Members of this enzyme subclass are activated by cell surface receptors and occur as heterodimers of enzymatic and regulatory subunits.
| Descriptor ID |
D058534
|
| MeSH Number(s) |
D08.811.913.696.620.500.100.100 D08.811.913.696.620.500.200.100 D12.776.476.162
|
| Concept/Terms |
Class I Phosphatidylinositol 3-Kinases- Class I Phosphatidylinositol 3-Kinases
- Class I Phosphatidylinositol 3 Kinases
- Class I Phosphatidylinositol 3-Kinase
- Class I Phosphatidylinositol 3 Kinase
- Phosphatidylinositol 3-Kinase, Class I
- Phosphatidylinositol 3 Kinase, Class I
|
Below are MeSH descriptors whose meaning is more general than "Class I Phosphatidylinositol 3-Kinases".
Below are MeSH descriptors whose meaning is more specific than "Class I Phosphatidylinositol 3-Kinases".
This graph shows the total number of publications written about "Class I Phosphatidylinositol 3-Kinases" by people in this website by year, and whether "Class I Phosphatidylinositol 3-Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Class I Phosphatidylinositol 3-Kinases" by people in Profiles.
-
Idelalisib activates AKT via increased recruitment of PI3Kd/PI3Kß to BCR signalosome while reducing PDK1 in post-therapy CLL cells. Leukemia. 2022 07; 36(7):1806-1817.
-
Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature. Head Neck Pathol. 2022 Jun; 16(2):416-426.
-
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Clin Cancer Res. 2021 01 15; 27(2):447-459.
-
Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med. 2019 12; 8(17):7322-7329.
-
Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors. Mol Divers. 2018 Feb; 22(1):95-112.
-
The driver landscape of sporadic chordoma. Nat Commun. 2017 10 12; 8(1):890.
-
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors. JAMA Oncol. 2016 Dec 01; 2(12):1565-1573.
-
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
-
Molecular profiling of head and neck squamous cell carcinoma. Head Neck. 2016 04; 38 Suppl 1:E1625-38.
-
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015 Aug; 14(4):644-58.